The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Chronic Hepatitis C Treatment

Direct-acting antiviral (DAA) therapy for chronic HCV infection achieving sustained virologic response (cure) in >95% of patients across all genotypes with pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) for 8-12 weeks, plus management of cirrhosis, HCC surveillance, and reinfection prevention.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is Chronic Hepatitis C Treatment?

Chronic hepatitis C virus (HCV) infection is the persistence of HCV RNA for >6 months after acute infection, occurring in 75-85% of acute cases. Global burden estimated 58 million people. Genotypes 1-6 have differing prevalence by region (1a/1b in Europe/Americas, 3 in South Asia, 4 in Egypt/Middle East). Disease progression includes asymptomatic chronic infection (often decades), progressive fibrosis (METAVIR F0-F4), cirrhosis (20% over 20-30 years), hepatocellular carcinoma (HCC, 1-4%/year in cirrhosis), liver failure, and need for transplantation. Extrahepatic manifestations include cryoglobulinemia, glomerulonephritis, lymphoma, type 2 diabetes, and cardiovascular disease.

Pre-treatment evaluation: confirmed HCV RNA positivity, HIV/HBV co-infection screening (HBV DNA important due to risk of HBV reactivation during DAA), assessment of comorbidities (renal function, drug-drug interactions especially with statins, antiretrovirals, anticonvulsants), pregnancy testing, and fibrosis staging. Non-invasive fibrosis assessment with transient elastography (FibroScan ≥12.5 kPa indicates cirrhosis), APRI, FIB-4, or other serum markers replaces routine biopsy. HCC surveillance with ultrasound and AFP every 6 months is mandated for advanced fibrosis (F3-F4)/cirrhosis.

Direct-acting antivirals (DAAs) revolutionized HCV treatment with cure rates >95% across genotypes. Pangenotypic regimens are preferred in modern era: sofosbuvir/velpatasvir (Epclusa) 400/100 mg daily for 12 weeks (8 weeks if no cirrhosis); glecaprevir/pibrentasvir (Mavyret) 300/120 mg daily for 8 weeks (12 weeks for treatment-experienced or genotype 3 cirrhosis); sofosbuvir/velpatasvir/voxilaprevir (Vosevi) 400/100/100 mg daily for 12 weeks for DAA-experienced patients (salvage therapy). Genotype-specific options remain: ledipasvir/sofosbuvir (Harvoni) for genotypes 1, 4, 5, 6; elbasvir/grazoprevir for genotypes 1, 4. Special populations: decompensated cirrhosis avoid protease inhibitors (use sofosbuvir/velpatasvir + ribavirin), renal impairment (glecaprevir/pibrentasvir or elbasvir/grazoprevir for severe), HIV coinfection (manage drug interactions, especially with cobicistat, ritonavir), HBV coinfection (monitor HBV DNA or treat HBV concurrently). SVR12 (undetectable HCV RNA 12 weeks post-treatment) defines cure. Post-SVR: continue HCC surveillance in advanced fibrosis/cirrhosis indefinitely; reinfection prevention via harm reduction (PWID), safer sex (HIV+/MSM), and risk counseling. Management of cirrhosis complications continues per usual care.

Symptoms

Often asymptomatic for decades
Fatigue, malaise (most common chronic symptom)
Right upper quadrant discomfort
Joint pain, myalgia
Pruritus (with cholestasis)
Jaundice, dark urine, pale stools (advanced)
Cirrhosis: ascites, encephalopathy, varices, edema
Cryoglobulinemic vasculitis: purpura, neuropathy, glomerulonephritis
Lichen planus, porphyria cutanea tarda

Risk Factors

Injection drug use (PWID, primary risk factor globally)
Blood transfusion before 1992
Healthcare workers (needlestick exposure)
Hemodialysis patients
HIV coinfection (especially MSM with HIV)
Born to HCV-positive mother (vertical transmission 5-7%)
Tattoos, piercings in unregulated settings
Sexual transmission (less common, higher in HIV+/MSM)
Egyptian birth (genotype 4, historic schistosomiasis)
Baby boomer cohort (1945-1965)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Positive HCV antibody screening (confirm with HCV RNA)
  • Chronic HCV infection (treatment evaluation)
  • Liver function abnormalities, fatigue
  • High-risk exposures, screening recommendations
  • Cirrhosis evaluation, HCC surveillance
  • Treatment failure, relapse after DAA
  • Decompensated liver disease (transplant evaluation)
  • HIV/HBV coinfection management
  • Pregnancy planning with chronic HCV

Treatment Methods

01
Pangenotypic: sofosbuvir/velpatasvir 12 weeks (8 if non-cirrhotic)
02
Pangenotypic: glecaprevir/pibrentasvir 8 weeks (most patients)
03
Salvage: sofosbuvir/velpatasvir/voxilaprevir 12 weeks (DAA-experienced)
04
Decompensated cirrhosis: sofosbuvir/velpatasvir + ribavirin
05
Renal impairment severe: glecaprevir/pibrentasvir or elbasvir/grazoprevir
06
HIV coinfection: manage drug-drug interactions
07
HBV coinfection: monitor or treat HBV concurrently
08
Lifestyle: alcohol abstinence, weight management
09
HCC surveillance: US + AFP every 6 months in F3/F4
10
Reinfection prevention: harm reduction, safer sex
11
Management of extrahepatic disease (cryoglobulinemia, glomerulonephritis)

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.